AARD Aardvark Therapeutics Inc

$AARD Net Cash/Sh: 4.35 The true value per share is likely over $10 Those shorting now will soon be ruined Shares Outstanding 21.88M Insider Ownership 41.42% Shares Float 12.82M Load up!

$AARD DON'T LET SHORTS GET COVERED. BUY BEFORE THE BIG WHALES COME $AARD 🚨 BUY NOW OR MISS THE MOVE?! 🤯🔥 UNDER $38M MARKET CAP vs. ~$80M CASH & OTHER ASSETS?! Trading WAY below reported cash & short-term investments alone! FDA HOLD LIFTED ✅ ARD-101 STILL ALIVE! If the pipeline gets back on track, upside could be MASSIVE! 🚀💥 HIGH RISK, HUGE POTENTIAL! #AARD #Biotech

$AARD The CTB (cost-to-borrow) for shorting shares has increased enormously—by 1,300%. Target $3+++

$AARD I usually don't pray and hope as an strategy when trading. I poured lots of cash into this stock as a principle Also, I don't tend to hold long let alone overnight. But I did both on this. This is way oversold and the market overeacted followed by the perfunctory shorting. In reality the overall news were good. Not fantastic but good. The hold was lifted snd the trials can resume. Initial results wre lackluster needing dosing adjustment and more research. The company has plenty of cash runway. So no offerings nor a R/S is on the horizon. So the market reaction so negativitily was not warranted. A reversal should be oncoming. I am not saying it gets back to $5. But I'd say anything in between $2.5 and $3.5 is fair.

Warned on $AARD, fell from $12 to $1 Warned on $SLS, today at $12 reached 80th event in AML phase 3 & reporting topline data soon GLTA- Please remember "live to fight another day" should be Priority #1 (reflected in position sizing)

$AARD This stock should be under 1$ today. maybe in AH. No cash big dilution and rs coming.

$AARD Great opportunity here on usual bio overreaction. In at 1.74 and will average down if it continues. Wayyyyy oversold.

$AARD this is where the game is obviously crooked , which we already know , up post market yesterday , up overnight and pre market 7:00am rug pull, the crooks say , “good doing bizness with ya pal” and the beat goes on .. I’m not in this but it’s sad for me to watch

$AARD Putting my Meta put money here lol Hopefully the data reads well tomorrow.... and this rips back over 12

$AARD About 9 million actual trading shares not owned by institutions: Shares outstanding 21.8M, Institutional ownership 52.10%, Number of floating shares 18.4M

$AARD this is interesting halted pending news. FDA lifted hold Aardvark Therapeutics Announces FDA Has Lifted the Clinical Hold on ARD-101 for the Treatment of Prader-Willi Syndrome and Will Host Webcast to Review the Available Exploratory Phase 3 HERO/OLE Data "Clinical development of ARD-101 for hyperphagia in Prader-Willi Syndrome (PWS) may resume Aardvark will host a webcast to review available dataset from the terminated Phase 3 HERO trial and OLE trial on Friday, October 23, 2026, at 8:00 a.m. EST" Unhalts at 4:35 PM

$AARD they should sell assets cover liabilities and disperse cash to shareholders , there would be at least 2.70 cash per share left and theyre left of the hook

$AARD time for management to think about bodyguards..........this is getting ugly for alot of people

$AARD all those that acting down and chasing will ALL get drowned !!!!!!! Once the algo sees everyone that bought and chasing 30-50% losss , it will keep falling as they will keep selling shares to cash out $$$$$ big times , check out FMTO loss 99% in 7 hours of trading. See you all Chasers at $1.05-1.10 soon I’m sorry $$$$$$

$AARD Some people here can’t see what is happening They release data to get things unhalted. Obviously that data looked like sh$t otherwise we would be at 25 right now and not going under 1…. Temporarily benefit…. Exploratory Efficacy Data: Because the Phase 3 HERO trial was halted early (randomizing 67 of the planned 90 participants), the efficacy data is strictly exploratory. Hunger questionnaire scores showed a modest reduction by Week 2 of dose escalation but returned near baseline after treatment stopped. The Path Forward: The company plans to request an FDA meeting to align on a new Phase 3 trial design using lower dosing structures, with clinical trials expected to resume in 2027

$AARD Redesigning a Phase 3 clinical trial can be both a good and a bad thing, depending on why it is being changed and how the redesign is executed. They are just lowering the mg to 100 from 200.

$AARD If you look at the S1 from the IPO, this company did private Series A, B and C rounds of investing before the IPO. And there is/was a large institutional ownership of the common shares as converted from preferred shares due to the IPO. To put that into perspective, this is normal. The institutions who own[ed] a large and significant number of shares also have Board representation. So where did the selling come from today? Lee the CEO owns a lot of shares. Any Board represented institution or Lee, if they sold today, will have to file an SEC form early next week. Keep a look out for SEC filings. Also, the price per share for the Series A stock was around $3.15 (split adjusted), Series B around $10 and Series C (DeChang led) around $15. This stock should have never IPO'd but was likely forced to, ahead of fully investigating ARD101 avoiding the own goal of too high a dose, by the greedy institutions looking for a quick exit.

$AARD The market has become a casino destroyed byb algorthims its almost as if the direction of the stock is decided before the news is released

$AARD Key Metrics Runway 8.4mo Cash $50.8M Burn/Q $18.2M Shares O/S 21.9M Baby Shelf No The live ATM and shelf create a major issuance overhang, while a moderate cash runway adds pressure to use them.

$AARD this company has almost $80 Million in cash and no debt. It's trading at $37 Million market cap, incredible.